Chemicals · NSE: ATUL
Atul
Q2 FY27 earnings highlights, from the results presentation
- M.Cap
- ₹15,105Cr
- P/E
- 19.6×
- 1Y return
- −13.28%
- From 52W high
- −28.5%
Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.
Share price
Results Q2 FY27, as filed · consolidated · ₹ Cr
| Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ | |
|---|---|---|---|---|---|
| Revenue | 1,877 | 1,552 | +21.0% | 1,848 | +1.6% |
| EBITDA | 247 | 267 | -7.8% | 394 | -37.3% |
| EBITDA margin | 13.1% | 17.2% | -410 bps | 21.3% | -816 bps |
| One-off items | 1 | — | — | — | — |
| PBTProfit before tax | 214 | 230 | -6.8% | 345 | -37.8% |
| Net profit | 156 | 179 | -13.1% | 245 | -36.5% |
| EPS (₹) | 52.89 | 60.88 | -13.1% | 83.32 | -36.5% |
From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures. In Q2 FY26 the filing tags the owners' profit as ₹88 Cr against its own period profit; the period profit less minority interest is shown.
In short
- 01Q2 revenue was Rs 1,877 crore, up 2% versus Q1.
- 02Q2 PBT margin was 11%, down 6% versus Q1, due to pricing pressure and lower inventory cost in Q1.
- 03Q2 EBITDA was Rs 295 crore and PAT Rs 159 crore, both lower than a year ago.
- 04Performance and Other Chemicals sales and profit rose on demand and better price realisation.
- 05Life Science Chemicals revenue was stagnant on lower crop protection volumes.
- 06A 50-50 water treatment chemicals JV with Buckman Laboratories started in 2026.
Segments
Performance and Other Chemicals: Performance and Other Chemicals sales and profit rose, driven by increased demand
Slides · p. 11
Performance and Other Chemicals: Performance and Other Chemicals sales and profit rose, driven by increased demand
“Recorded higher sales and profitability in the Performance and Other Chemicals segment, driven by increased demand and”
Life Science Chemicals: Life Science Chemicals revenue stagnant due to lower crop protection volumes
Slides · p. 11
Life Science Chemicals: Life Science Chemicals revenue stagnant due to lower crop protection volumes
“Reported stagnant revenue in the Life Science Chemicals segment due to lower volumes in the crop protection chemicals”
Performance and Other Chemicals; Life Science Chemicals; Others: Segment half-year revenue: Rs 2,783 crore (up 33%), Rs 897 crore (up 1%), Rs 45 crore (up 5%)
Slides · p. 11
Performance and Other Chemicals; Life Science Chemicals; Others: Segment half-year revenue: Rs 2,783 crore (up 33%), Rs 897 crore (up 1%), Rs 45 crore (up 5%)
“Revenue 2,783 2,098 33% 897 889 1% 45 43 5% - - -”
Performance and Other Chemicals; Life Science Chemicals; Others: Segment PBIT: Rs 368 crore (up 80%), Rs 163 crore (down 3%), Rs 6 crore (down 30%)
Slides · p. 11
Performance and Other Chemicals; Life Science Chemicals; Others: Segment PBIT: Rs 368 crore (up 80%), Rs 163 crore (down 3%), Rs 6 crore (down 30%)
“PBIT 368 204 80% 163 169 (3%) 6 9 (30%) 24 26 (9%)”
Margins and costs
Q2 PBT margin 11%, down 6% versus Q1, due to pricing pressure and lower Q1 inventory cost
Slides · p. 9
Q2 PBT margin 11%, down 6% versus Q1, due to pricing pressure and lower Q1 inventory cost
“Reported PBT margin of 11%, down 6% versus Q1, due to pricing pressure, lower inventory cost in Q1 and”
Q2 EBITDA Rs 295 crore versus Rs 316 crore a year ago, down 7%
Slides · p. 9
Q2 EBITDA Rs 295 crore versus Rs 316 crore a year ago, down 7%
“EBITDA 295 316 (7%) 427 (31%) 722 578 25%”
Q2 EBITDA margin 16% versus 20% a year ago and 23% in Q1
Slides · p. 9
Q2 EBITDA margin 16% versus 20% a year ago and 23% in Q1
“EBITDA % 16% 20% (5%) 23% (7%) 19% 19% -”
Performance and Other Chemicals: Performance and Other Chemicals price realisation rose in line with higher input prices
Slides · p. 11
Performance and Other Chemicals: Performance and Other Chemicals price realisation rose in line with higher input prices
“better price realisation across sub-segments in line with higher input prices.”
Life Science Chemicals: Life Science Chemicals profitability hit by higher input prices
Slides · p. 11
Life Science Chemicals: Life Science Chemicals profitability hit by higher input prices
“sub-segment despite better price realisation, while higher input prices impacted profitability.”
Debt and working capital
Working capital increased as trade receivables grew
Slides · p. 10
Working capital increased as trade receivables grew
“Increased working capital as trade receivables grew”
Inventories Rs 993 crore versus Rs 816 crore
Slides · p. 10
Inventories Rs 993 crore versus Rs 816 crore
“Inventories 993 816”
Current investments Rs 1,880 crore versus Rs 1,655 crore
Slides · p. 10
Current investments Rs 1,880 crore versus Rs 1,655 crore
“Current investments 1,880 1,655”
Trade receivables Rs 1,390 crore at September 30, 2026 versus Rs 1,271 crore
Slides · p. 10
Trade receivables Rs 1,390 crore at September 30, 2026 versus Rs 1,271 crore
“Trade receivables 1,390 1,271”
Inventory rose due to higher prices and higher work-in-progress
Slides · p. 10
Inventory rose due to higher prices and higher work-in-progress
“due to higher prices and higher work-in-progress”
Acquisitions and new business
50-50 JV with Buckman Laboratories for water treatment chemicals, from 2026
Slides · p. 8
50-50 JV with Buckman Laboratories for water treatment chemicals, from 2026
“Buckman Laboratories Atul-Buckman 50-50 2026 ... Water treatment chemicals”
Commercialised Halosulfuron herbicide
Slides · p. 13
Commercialised Halosulfuron herbicide
“Commercialised Halosulfuron”
New launches include Marble Cleaner, Tile Cleaner and Protack D3
Slides · p. 15
New launches include Marble Cleaner, Tile Cleaner and Protack D3
“Marble Cleaner and Tile Cleaner Protack D3”
Other
Q2 revenue Rs 1,877 crore, up 2% versus Q1
Slides · p. 9
Q2 revenue Rs 1,877 crore, up 2% versus Q1
“Delivered revenue of ₹ 1,877 cr, up 2% versus Q1.”
Q2 PAT Rs 159 crore versus Rs 182 crore a year ago, down 13%
Slides · p. 9
Q2 PAT Rs 159 crore versus Rs 182 crore a year ago, down 13%
“PAT 159 182 (13%) 254 (37%) 413 315 31%”
Executed a 3 MW solar power agreement
Slides · p. 13
Executed a 3 MW solar power agreement
“Executed a 3 MW solar power agreement”
Atul Foundation Health Center added an Ophthalmology Department
Slides · p. 14
Atul Foundation Health Center added an Ophthalmology Department
“the addition of an Ophthalmology Department.”
Q2 revenue up 21% on a year ago; half-year revenue Rs 3,725 crore, up 23%
Slides · p. 9
Q2 revenue up 21% on a year ago; half-year revenue Rs 3,725 crore, up 23%
“Revenue 1,877 1,552 21% 1,848 2% 3,725 3,030 23%”
Sources
- Investor presentation, Q2 FY27 Filed 24 Oct 2026 on BSE · 21 pages
Management's own statements, quoted from its BSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

